SOLV Energy upgraded by UBS with a new price target
UBS upgraded SOLV Energy (MWH) from Neutral to Buy with a $37.00 price target. The stock has shown varied reactions to past headlines, with a median move of 4.5%.
Solventum Corp
Solventum develops, manufactures and commercializes healthcare products and services for hospitals, physicians, clinics and other healthcare providers around the world. Its products and services support patient care from prevention and diagnosis through treatment and recovery. Solventum is headquartered in Eagan, Minnesota. Solventum has three business segments. MedSurg offers wound care, skin care, surgical supplies, infection prevention products and medical technologies. Dental Solutions sells dental and orthodontic products, including brackets, aligners, restorative cements and bonding agents. Health Information Systems provides healthcare software for clinical documentation, coding, revenue cycle processes and data visualization. The company makes money by selling products and software through direct sales, distributors, key account management, inside sales and e-commerce, with local partners supporting sales in emerging geographies. It sells in over 90 countries.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SOLV in the last 30 days.
See all $SOLV insider activity →UBS upgraded SOLV Energy (MWH) from Neutral to Buy with a $37.00 price target. The stock has shown varied reactions to past headlines, with a median move of 4.5%.
TD Cowen kept its Buy rating on SOLV Energy and increased its price target to $37 from $35, suggesting a 33% upside from the Nov 13 close of $27.81, according to the firm.
SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, and raised full-year guidance. Net income rose 75% to $123M, but margins compressed. The company's backlog reached $9.2B, and it acquired ASB Energy Services for $45M. Shares fell 1.02% to $27.30 despite strong results.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SOLV (Solventum Corp). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.
Recent SOLV coverage spans earnings, financial news and market movers.
The upgrade and new target are likely to support near-term sentiment and attract incremental dip-buying, absent other new fundamentals.
The PT increase is likely to support near-term sentiment and can attract incremental dip-buying, though it is not a fundamental disclosure.
Guidance raise may lift the stock despite recent decline; margin compression tempers upside.
Guidance raise suggests stronger future earnings.
Analyst upgrade and higher guidance suggest upside potential.
AlphAI scores every news story that mentions SOLV with an AI model for sentiment and relevance, and aggregates insider trades from Solventum Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS upgraded SOLV Energy (MWH) from Neutral to Buy with a $37.00 price target. The stock has shown varied reactions to past headlines, with a median move of 4.5%.
TD Cowen kept its Buy rating on SOLV Energy and increased its price target to $37 from $35, suggesting a 33% upside from the Nov 13 close of $27.81, according to the firm.
SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, and raised full-year guidance. Net income rose 75% to $123M, but margins compressed. The company's backlog reached $9.2B, and it acquired ASB Energy Services for $45M. Shares fell 1.02% to $27.30 despite strong results.
SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, with net income of $123M. Adjusted EBITDA was $173M, and gross margin was 17.8%. The company raised its 2026 guidance for revenue, adjusted gross profit, and adjusted EBITDA. Growth was driven by new construction and existing infrastructure revenue. SOLV completed its acquisition of ASB Energy Services in October 2026.
BTIG raised its price target for Solventum Holdings (SOLV) to $100 after strong Q3 results. SOLV reported $1.949B revenue and $1.45 EPS, beating estimates. The company raised guidance for organic growth, operating margins, and EPS. BTIG cited operational execution and cost management as key factors.
Solventum reported Q3 sales of $1.9B, with mixed performance across segments. Gross margin rose to 57.1%, while operating margin fell to 19.9%. The company raised its full-year earnings outlook to $7.20-$7.30 per share and expects high-end organic sales growth. It also announced plans to separate its Health Information Systems business and renegotiated a raw material supply agreement with 3M.
Solventum (NYSE:SOLV) has completed over 90% of its separation from 3M, including an ERP cutover and renegotiated supply agreement. The company plans to separate its Health Information Systems business, which may impact operating margins. Management aims to provide more details in November 2026. Analysts warn of potential earnings quality issues and execution risks.
Wells Fargo kept Solventum at Equal-Weight, raising its price target to $95 from $89, a 6.7% increase. This implies a 9.0% upside from the Nov 5 close of $87.18.
Piper Sandler kept Solventum's rating at Overweight and increased its price target to $110 from $105, suggesting a 26.2% upside from the Nov 5 close of $87.18.
Solventum (NYSE: SOLV) reported Q3 2026 sales of $1.9B, down 7.0% YoY, with organic sales down 2.8%. Adjusted EPS was $1.45, down 3.6%. The company expects full-year organic sales growth toward the high end of +2.5% to +3.0% and raised adjusted EPS guidance to $7.20-$7.30. Operating cash flow was $177M, and free cash flow was $97M. The company completed ERP system cutovers and exited ~90% of 3M transition service agreements.